Limits...
Global programme to eliminate lymphatic filariasis: the processes underlying programme success.

Ichimori K, King JD, Engels D, Yajima A, Mikhailov A, Lammie P, Ottesen EA - PLoS Negl Trop Dis (2014)

View Article: PubMed Central - PubMed

Affiliation: Department of Control of Neglected Tropical Diseases, World Health Organization, Geneva, Switzerland.

AUTOMATICALLY GENERATED EXCERPT
Please rate it.

Lymphatic filariasis (LF) is caused by filarial worms that live in the lymphatic system and commonly lead to lymphoedema, elephantiasis, and hydrocele... Global momentum to eliminate LF has developed over the past 15 years as a result not only of research demonstrating the value of single-dose treatment strategies and point-of-care diagnostic tools, but also of both the generous donations of medicines from the following committed pharmaceutical companies: GlaxoSmithKline (albendazole), Merck (ivermectin), and Eisai (diethylcarbamazine; DEC), and the essential financial support for programme implementation from the donor community... The MMDP component of the GPELF has the principal aim to provide access to basic recommended care, for every person with acute dermatolymphangioadenitis (ADLA), lymphedema, elephantiasis, or hydrocele in all areas where LF is endemic, thus alleviating suffering and promoting improvement in their quality of life... The recommended minimum package of care includes: treating episodes of ADLA/acute attacks among people with lymphoedema or elephantiasis, preventing both the debilitating and painful episodes of ADLA or acute attacks and the progression of lymphoedema or elephantiasis, enhancing access to hydrocele surgery, and providing antifilarial medicines through MDA or individual treatment to destroy any remaining worms and microfilariae... Intensive research efforts are focused on development and validation of new surveillance tools and strategies (such as the use of antibody assays to reflect exposure to infective larvae and xenomonitoring to confirm absence of parasites in the vectors), both to document the interruption of transmission of LF and to harmonize the process for verifying the elimination of LF with WHO verification processes for other diseases.

No MeSH data available.


Related in: MedlinePlus

Selected opportunities for integrating lymphatic filariasis activities into programmes for other diseases [21].
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4263400&req=5

pntd-0003328-g002: Selected opportunities for integrating lymphatic filariasis activities into programmes for other diseases [21].

Mentions: The GPELF is now part of integrated efforts to prevent and treat NTDs, in which MDA, VC. and morbidity management are increasingly integrated and delivered as multi-intervention packages at the global, national, and local levels (Fig. 2) [8], [13], [29], [30].


Global programme to eliminate lymphatic filariasis: the processes underlying programme success.

Ichimori K, King JD, Engels D, Yajima A, Mikhailov A, Lammie P, Ottesen EA - PLoS Negl Trop Dis (2014)

Selected opportunities for integrating lymphatic filariasis activities into programmes for other diseases [21].
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4263400&req=5

pntd-0003328-g002: Selected opportunities for integrating lymphatic filariasis activities into programmes for other diseases [21].
Mentions: The GPELF is now part of integrated efforts to prevent and treat NTDs, in which MDA, VC. and morbidity management are increasingly integrated and delivered as multi-intervention packages at the global, national, and local levels (Fig. 2) [8], [13], [29], [30].

View Article: PubMed Central - PubMed

Affiliation: Department of Control of Neglected Tropical Diseases, World Health Organization, Geneva, Switzerland.

AUTOMATICALLY GENERATED EXCERPT
Please rate it.

Lymphatic filariasis (LF) is caused by filarial worms that live in the lymphatic system and commonly lead to lymphoedema, elephantiasis, and hydrocele... Global momentum to eliminate LF has developed over the past 15 years as a result not only of research demonstrating the value of single-dose treatment strategies and point-of-care diagnostic tools, but also of both the generous donations of medicines from the following committed pharmaceutical companies: GlaxoSmithKline (albendazole), Merck (ivermectin), and Eisai (diethylcarbamazine; DEC), and the essential financial support for programme implementation from the donor community... The MMDP component of the GPELF has the principal aim to provide access to basic recommended care, for every person with acute dermatolymphangioadenitis (ADLA), lymphedema, elephantiasis, or hydrocele in all areas where LF is endemic, thus alleviating suffering and promoting improvement in their quality of life... The recommended minimum package of care includes: treating episodes of ADLA/acute attacks among people with lymphoedema or elephantiasis, preventing both the debilitating and painful episodes of ADLA or acute attacks and the progression of lymphoedema or elephantiasis, enhancing access to hydrocele surgery, and providing antifilarial medicines through MDA or individual treatment to destroy any remaining worms and microfilariae... Intensive research efforts are focused on development and validation of new surveillance tools and strategies (such as the use of antibody assays to reflect exposure to infective larvae and xenomonitoring to confirm absence of parasites in the vectors), both to document the interruption of transmission of LF and to harmonize the process for verifying the elimination of LF with WHO verification processes for other diseases.

No MeSH data available.


Related in: MedlinePlus